Heidi Högel1, Eero Rissanen1, Christian Barro2, Markus Matilainen1, Marjo Nylund1, Jens Kuhle2, Laura Airas1. 1. Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland/Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland. 2. Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression. Now, both biomarkers can be detected reliably in serum, and importantly, their serum levels correlate well with their CSF levels. OBJECTIVE: To evaluate the usability of serum GFAP measurement as a biomarker of progressive disease and disease severity in MS. METHODS: Clinical course, Expanded Disability Status Scale (EDSS), disease duration, patient age and magnetic resonance imaging (MRI) parameters were reviewed in 79 MS patients in this cross-sectional hospital-based study. Serum samples were collected for measurement of GFAP and NfL concentrations using single molecule array (Simoa) assay. A cohort of healthy controls was evaluated for comparison. RESULTS: Higher serum concentrations of both GFAP and NfL were associated with higher EDSS, older age, longer disease duration, progressive disease course and MRI pathology. CONCLUSION: Earlier studies have demonstrated that GFAP, unlike NfL, is not increased in association with acute focal inflammation-related nervous system damage. Our work suggests that GFAP serum level associates with disease progression in MS and could potentially serve as an easily measurable biomarker of central nervous system (CNS) pathology related to disease progression in MS.
BACKGROUND: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression. Now, both biomarkers can be detected reliably in serum, and importantly, their serum levels correlate well with their CSF levels. OBJECTIVE: To evaluate the usability of serum GFAP measurement as a biomarker of progressive disease and disease severity in MS. METHODS: Clinical course, Expanded Disability Status Scale (EDSS), disease duration, patient age and magnetic resonance imaging (MRI) parameters were reviewed in 79 MSpatients in this cross-sectional hospital-based study. Serum samples were collected for measurement of GFAP and NfL concentrations using single molecule array (Simoa) assay. A cohort of healthy controls was evaluated for comparison. RESULTS: Higher serum concentrations of both GFAP and NfL were associated with higher EDSS, older age, longer disease duration, progressive disease course and MRI pathology. CONCLUSION: Earlier studies have demonstrated that GFAP, unlike NfL, is not increased in association with acute focal inflammation-related nervous system damage. Our work suggests that GFAP serum level associates with disease progression in MS and could potentially serve as an easily measurable biomarker of central nervous system (CNS) pathology related to disease progression in MS.
Authors: Carlos Camara-Lemarroy; Luanne Metz; Jens Kuhle; David Leppert; Eline Willemse; David Kb Li; Anthony Traboulsee; Jamie Greenfield; Graziela Cerchiaro; Claudia Silva; V Wee Yong Journal: Mult Scler Date: 2022-07-18 Impact factor: 5.855
Authors: Sage E Hawn; Zoe Neale; Erika J Wolf; Xiang Zhao; Meghan Pierce; Dana Fein-Schaffer; William Milberg; Regina McGlinchey; Mark Logue; Mark W Miller Journal: Depress Anxiety Date: 2022-03-21 Impact factor: 8.128
Authors: Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2022-02-03 Impact factor: 44.711
Authors: Ahmed Abdelhak; Andre Huss; Alexander Stahmann; Makbule Senel; Markus Krumbholz; Markus C Kowarik; Joachim Havla; Tania Kümpfel; Ingo Kleiter; Isabella Wüstinger; Uwe K Zettl; Margit Schwartz; Romy Roesler; Tim Friede; Albert C Ludolph; Ulf Ziemann; Hayrettin Tumani Journal: Contemp Clin Trials Commun Date: 2020-05-19
Authors: Orhan Aktas; Michael A Smith; William A Rees; Jeffrey L Bennett; Dewei She; Eliezer Katz; Bruce A C Cree Journal: Ann Neurol Date: 2021-03-30 Impact factor: 10.422